174316-26-8

Basic information

• Product Name: N-methyl-α-cyclohexylbenzenemethanamine
• Synonyms: N-methyl-α-cyclohexylbenzenemethanamine
• CAS NO: 174316-26-8
• Molecular Weight: 203.327
• Mol File: 174316-26-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-methyl-α-cyclohexylbenzenemethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-α-cyclohexylbenzenemethanamine(174316-26-8)
• EPA Substance Registry System: N-methyl-α-cyclohexylbenzenemethanamine(174316-26-8)

Safety Data

• Hazardous Substances Data: 174316-26-8(Hazardous Substances Data)

Upstream product

• 712-50-5 Cyclohexyl phenyl ketone 
• 42071-06-7 N-(cyclohexyl(phenyl)methyl)formamide 
• 622-29-7 N-Benzylidenemethylamine 
• 931-50-0 cyclohexylmagnesium bromide 

Downstream Products

• 119746-99-5 2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-{2-[(cyclohexyl-phenyl-methyl)-methyl-amino]-ethyl} ester 5-methyl ester 
• 116210-81-2 2-(Cyclohexyl-methyl-amino)-N-(cyclohexyl-phenyl-methyl)-N-methyl-acetamide 
• 116210-80-1 2-Cyclohexylamino-N-(cyclohexyl-phenyl-methyl)-N-methyl-acetamide 
• 119747-12-5 3-Oxobutanoic acid 2-<(cyclohexylphenylmethyl)methylamino>ethyl ester 
• 119747-09-0 3-Amino-2-butenoic acid 2-<(cyclohexylphenylmethyl)methylamino>ethyl ester 
• 116210-92-5 N-methyl-N-(cyclohexylphenylmethyl)-2-chloroacetamide 

Relevant articles and documents

Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with PotentIn VitroAntiproliferative Activity

Heme oxygenase-1 (HO-1) promotes heme catabolism exercising cytoprotective roles in normal and cancer cells. Herein, we report the design, synthesis, molecular modeling, and biological evaluation of novel HO-1 inhibitors. Specifically, an amide linker in the central spacer and an imidazole were fixed, and the hydrophobic moiety required by the pharmacophore was largely modified. In many tumors, overexpression of HO-1 correlates with poor prognosis and chemoresistance, suggesting the inhibition of HO-1 as a possible antitumor strategy. Accordingly, compounds7iand7l-pemerged for their potency against HO-1 and were investigated for their anticancer activity against prostate (DU145), lung (A549), and glioblastoma (U87MG, A172) cancer cells. The selected compounds showed the best activity toward U87MG cells. Compound7lwas further investigated for its in-cell enzymatic HO-1 activity, expression levels, and effects on cell invasion and vascular endothelial growth factor (VEGF) extracellular release. The obtained data suggest that7lcan reduce cell invasivity acting through modulation of HO-1 expression.